Product Description
a humanized monoclonal antibody. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05186285)
Mechanisms of Action: MASP2 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kangnuoya Biomedical Technology (Chengdu) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glomerulonephritis|IgA Nephropathy|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05775042 |
CM338-105101 | P2 |
Recruiting |
Kidney Diseases|IgA Nephropathy|Glomerulonephritis |
2027-06-30 |
12% |
2023-08-01 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20220779 |
CTR20220779 | P1 |
Active, not recruiting |
IgA Nephropathy |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20230619 |
CTR20230619 | P2 |
Recruiting |
IgA Nephropathy |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|